

Supplementary Online Content

Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome. *JAMA Neurol*. Published online June 5, 2017. doi:10.1001/jamaneurol.2017.0934

eTable 1. *HLA-DRB1* alleles in patients with antisynthetase syndrome and healthy individuals

eTable 2. Comparison between patients with and without anti-OJ antibodies

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. HLA-DRB1 alleles in patients with antisynthetase syndrome and healthy individuals

HLA	All anti-ARS (allele N=96) N (%)	Anti-Jo-1 (allele N=30) N (%)	Anti-OJ (allele N=22) N (%)	Anti-PL-7 (allele N=24) N (%)	Control (allele N=920) N (%)
DRB1*01:01	6 (6%)	2 (7%)	0 (0%)	4 (17%)	58 (6%)
DRB1*03:01	1 (1%)	0 (0%)	1 (5%)	0 (0%)	1 (0%)
DRB1*04:01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	11 (1%)
DRB1*04:03	1 (1%)	1 (3%)	0 (0%)	0 (0%)	23 (3%)
DRB1*04:05	12 (13%)	5 (17%)	2 (9%)	3 (13%)	103 (11%)
DRB1*04:06	3 (3%)	0 (0%)	1 (5%)	0 (0%)	33 (4%)
DRB1*04:07	1 (1%)	0 (0%)	0 (0%)	0 (0%)	5 (5%)
DRB1*04:10	2 (2%)	0 (0%)	0 (0%)	2 (8%)	14 (2%)
DRB1*07:01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
DRB1*08:02	7 (7%)	4 (13%)	0 (0%)	2 (8%)	53 (6%)
DRB1*08:03	10 (10%)	3 (10%)	2 (9%)	4 (17%)	71 (6%)
DRB1*09:01	10 (10%)	2 (7%)	4 (18%)	3 (13%)	128 (14%)
DRB1*10:01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (0%)
DRB1*11:01	4 (4%)	2 (7%)	1 (5%)	1 (4%)	23 (3%)
DRB1*12:01	1 (1%)	1 (3%)	0 (0%)	0 (0%)	32 (3%)
DRB1*12:02	2 (2%)	0 (0%)	2 (9%)	0 (0%)	19 (2%)
DRB1*13:01	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (0%)
DRB1*13:02	3 (3%)	1 (3%)	0 (0%)	0 (0%)	68 (7%)
DRB1*13:03	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
DRB1*13:07	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
DRB1*14:03	1 (1%)	1 (3%)	0 (0%)	0 (0%)	13 (1%)
DRB1*14:05	3 (3%)	0 (0%)	2 (9%)	1 (4%)	25 (3%)
DRB1*14:06	0 (0%)	0 (0%)	0 (0%)	0 (0%)	12 (1%)
DRB1*14:12	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
DRB1*14:54	6 (6%)	2 (7%)	2 (9%)	0 (0%)	37 (4%)
DRB1*15:01	10 (10%)	1 (3%)	3 (14%)	2 (8%)	62 (7%)
DRB1*15:02	10 (10%)	4 (13%)	2 (9%)	2 (8%)	114 (12%)
DRB1*16:02	2 (2%)	1 (3%)	0 (0%)	0 (0%)	6 (1%)

ARS, aminoacyl transfer RNA synthetase; HLA, human leukocyte antigen

eTable 2. Comparison between patients with and without anti-OJ antibodies

	Anti-OJ (N=14) N (%)	Non-anti-OJ (N=37) N (%)	p value
Number of women	7 (50%)	24 (65%)	0.36
Age at disease onset (yrs)	67.7 ± 12.8	57.4 ± 16.5	0.04
Disease progression			
Subacute	13 (93%)	33 (89%)	0.69
Chronic	1 (7%)	4 (11%)	0.69
Risk factors			
Antecedent infection	3 (21%)	7 (19%)	1.00
Statin	0 (0%)	1 (3%)	0.53
Cancer	3 (21%)	3 (8%)	0.19
Systemic autoimmune disease	1 (7%)	7 (19%)	0.30
Muscle weakness			
Severe limb muscle weakness	8 (57%)	6 (16%)	0.01
Neck muscle weakness	8 (57%)	9 (24%)	0.04
Dysphagia	8 (57%)	7 (19%)	0.01
Respiratory muscle involvement	1 (7%)	5 (14%)	0.33
Muscle atrophy	8 (57%)	7 (19%)	0.01
Myalgia	7 (50%)	8 (22%)	0.05
Extramuscular symptoms			
Fever	7 (50%)	13 (35%)	0.33
Skin rash	8 (57%)	26 (70%)	0.37
Arthropathy	4 (29%)	17 (46%)	0.26
Raynaud phenomenon	0 (0%)	4 (11%)	0.20
Interstitial lung disease	12 (86%)	29 (78%)	0.56
Blood examination			
Creatine kinase (IU/L)	6207 ± 6612	3561 ± 4169	0.09
Histological findings			
Myofiber necrosis in perifascicular regions	6/13 (46%)	18/37 (49%)	1.00
Diffuse myofiber necrosis	5/13 (38%)	3/37 (8%)	0.03
MHC class I expression	11/13 (85%)	30/37 (81%)	1.00
MHC class I enhancement in perifascicular regions	3/13 (23%)	9/37 (24%)	1.00
MHC class II expression	7/13 (54%)	12/37 (32%)	0.50
MHC class II enhancement in perifascicular regions	7/13 (54%)	9/37 (24%)	0.30

MHC; major histocompatibility complex